Angiogenesis inhibitors in tackling recurrent glioblastoma

References

• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17:iv1–iv62.
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
   PubMed Web of Science ®Google Scholar
• Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.
   PubMed Web of Science ®Google Scholar
• Stummer W, Tonn J-C-C, Mehdorn HM, et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg. 2011;114:613–623.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. Jama. 2015;314:2535–2543.
   PubMed Web of Science ®Google Scholar
• Wick W. TTFields: where does all the skepticism come from? Neuro Oncol. 2016;18:303–305.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Weller M, Tabatabai G, Kästner B, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive Glioblastoma: the DIRECTOR Trial. Clin Cancer Res. 2015;21:2057–2064.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31:3212–3218.
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28:1168–1174.
   PubMed Web of Science ®Google Scholar
• Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma- An update. Crit Rev Oncol Hematol. 2016;99:389–408.
   PubMed Web of Science ®Google Scholar
• Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15:e395-403.
   PubMed Web of Science ®Google Scholar
• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192–2202.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Labussière M, Cheneau C, Prahst C, et al. Angiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastoma. Cancer Invest. 2016;7907:1–6.
   Google Scholar
• Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 2012;124:763–775.
   PubMed Web of Science ®Google Scholar
• Mao JM, Liu J, Guo G, et al. Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets. Biomark Res. 2015;3:8.
   PubMed Web of Science ®Google Scholar
• Lu-Emerson C, Duda DG, Emblem KE, et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with Glioblastoma. J Clin Oncol. 2015;33:1197–1213.
   PubMed Web of Science ®Google Scholar
• Jahangiri A, De Lay M, Miller LM, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013;19:1773–1783.
   PubMed Web of Science ®Google Scholar
• Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 2011;6:2.
   PubMed Web of Science ®Google Scholar
• Zhang M, Ye G, Li J, et al. Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy. Brain Tumor Pathol. 2015;32:229–236.
   PubMed Web of Science ®Google Scholar
• Rege TA, Stewart J, Dranka B, et al. Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol. 2009;218:94–103.
   PubMed Web of Science ®Google Scholar
• Rege TA, Fears CY, Gladson CL. Endogenous inhibitors of angiogenesis in malignant gliomas: nature’s antiangiogenic therapy. Neuro Oncol. 2005;7:106–121.
   PubMed Web of Science ®Google Scholar
• Zhou YH, Tan F, Hess KR, et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003;9:3369–3375.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Szabo E, Burghardt I, et al. Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. Oncotarget. 2015;6:22480–22495.
   PubMed Web of Science ®Google Scholar
• De Bonis P, Marziali G, Vigo V, et al. Antiangiogenic therapy for high-grade gliomas: current concepts and limitations. Expert Rev Neurother. 2013;13:1263–1270.
   PubMed Web of Science ®Google Scholar
• De Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American brain tumor consortium study. J Clin Oncol. 2011;29:2689–2695.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Reardon DA, de Groot JF, et al. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014;20:5612–5619.
   PubMed Web of Science ®Google Scholar
• Wang SY, Ke YQ, Lu GH, et al. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. J Neurooncol. 2013;112:339–345.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TSTS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–722.
   PubMed Web of Science ®Google Scholar
• Wick W, Brandes A, Gorlia T, et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial. Neuro Oncol. 2015;17:v1.5-v1.
   Google Scholar
• Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1100–1108.
   PubMed Web of Science ®Google Scholar
• Verhoeff JJC, van Tellingen O, Claes A, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009;9:444.
   PubMed Web of Science ®Google Scholar
• Wick W, Weller M, van den Bent M, et al. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol. 2010;28:e188–e189.
   PubMed Web of Science ®Google Scholar
• Stupp R, Weller M. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro Oncol. 2014;16:765–767.
   PubMed Web of Science ®Google Scholar
• Levin VA, Mendelssohn ND, Chan J, et al. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol. 2015;122:145–150.
   PubMed Web of Science ®Google Scholar
• Lorgis V, Maura G, Coppa G, et al. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol. 2012;107:351–358.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gerstner ER, Emblem KE, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013;110:19059–19064. United States.
   PubMed Web of Science ®Google Scholar
• Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553–563.
   PubMed Web of Science ®Google Scholar
• Von Baumgarten L, Brucker D, Tirniceru A, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 2011;17:6192–6205.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DAM, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1–32.
   PubMed Web of Science ®Google Scholar
• DeLay M, Jahangiri A, Carbonell WS, et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res. 2012;18:2930–2942.
   PubMed Web of Science ®Google Scholar
• Barajas RF, Butowski NA, Phillips JJ, et al. The development of reduced diffusion following bevacizumab therapy identifies regions of recurrent disease in patients with high-grade glioma. Acad Radiol. 2016;23:1073–1082.
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Emblem KE, Sorensen GA. Vascular magnetic resonance imaging in brain tumors during antiangiogenic therapy—are we there yet? Cancer J. 2015;21:337–342.
   PubMed Web of Science ®Google Scholar
• Niyazi M, Harter PN, Hattingen E, et al. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget. 2016;7:2313–2328.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205–2218.
   PubMed Web of Science ®Google Scholar
• McGee MC, Hamner JB, Williams RF, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 2010;76:1537–1545.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–4740.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–745.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schäfer N, Steinbach JP, et al. Bevacizumab Plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol. 2016;34:1611–1619.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Reardon DA. The future of antiangiogenic treatment in glioblastoma. Curr Opin Neurol. 2014;27:675–682.
   PubMed Web of Science ®Google Scholar
• Wen PY, Norden AD, Drappatz J, et al. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010;12:68–75.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Macdonald DR, Abrey LE, et al. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013;13:347.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15:1329–1334.
   PubMed Web of Science ®Google Scholar
• Taphoorn MJB, Henriksson R, Bottomley A, et al. Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol. 2015;33:2166–2175.
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Wick A, et al. Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol. 2016;18:315–328.
   PubMed Web of Science ®Google Scholar
• Dirven L, Van Den Bent MJ, Bottomley A, et al. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer. 2015;51:1321–1330.
   PubMed Web of Science ®Google Scholar
• Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in avaglio. Neuro Oncol. 2012;14:vi101.
   Google Scholar
• Brown PD, Jensen AW, Felten SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24:5427–5433.
   PubMed Web of Science ®Google Scholar
• Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013;14:e407–e416.
   PubMedGoogle Scholar
• Taal W, Oosterkamp HM, Walenkamp AME, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943–953.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Taal W. Bevacizumab alone or in combination with chemotherapy in glioblastomas?-Authors’ reply. Lancet Oncol. 2014;15:e473–e474.
   PubMed Web of Science ®Google Scholar
• Field KM, Simes J, Nowak AK, et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 2015;17:1504–1513.
   PubMed Web of Science ®Google Scholar
• Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12:6144–6152.
   PubMed Web of Science ®Google Scholar
• Cloughesy T, Finocchiaro G, Belda-Iniesta C, et al. Phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma. Neuro Oncol. 2014;16:v81.
   PubMed Web of Science ®Google Scholar
• Kil WJ, Tofilon PJ, Camphausen K. Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol. 2012;7:25.
   PubMed Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156–163.
   PubMed Web of Science ®Google Scholar
• Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79:1487–1495.
   PubMed Web of Science ®Google Scholar
• Louveau A, Harris TH, Kipnis J. Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 2015;36:569–577.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17:1064–1075.
   PubMed Web of Science ®Google Scholar
• Lampson LA. Brain tumor immunotherapy: seeing the brain in the body. Drug Discov Today. 2013;18:399–406.
   PubMed Web of Science ®Google Scholar
• Jackson CM, Lim M, Drake CG. Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res. 2014;20:3651–3659.
   PubMed Web of Science ®Google Scholar
• Garber ST, Hashimoto Y, Weathers S-P, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016;18:1357–1366.
   PubMed Web of Science ®Google Scholar
• Preusser M, Lim M, Hafler DA, et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11:504–514.
   PubMed Web of Science ®Google Scholar
• Neagu MR, Reardon DA. An update on the role of immunotherapy and vaccine strategies for primary brain tumors. Curr Treat Options Oncol. 2015;16:1–18.
   Web of Science ®Google Scholar
• Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015;17(Suppl 7):vii9–vii14.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Nevala WK, Lieser EAT, et al. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology. 2013;2:e24436.
   PubMed Web of Science ®Google Scholar
• Terme M, Colussi O, Marcheteau E, et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2012;2012:492920.
   PubMedGoogle Scholar
• Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150–4166.
   PubMed Web of Science ®Google Scholar
• Laxmanan S, Robertson SW, Wang E, et al. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun. 2005;334:193–198.
   PubMed Web of Science ®Google Scholar
• Ziogas AC, Gavalas NG, Tsiatas M, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer. 2012;130:857–864.
   PubMed Web of Science ®Google Scholar
• Buchroithner J, Pichler J, Marosi C, et al. Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. Int J Clin Pharmacol Ther. 2014;52:76–77.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Schuster J, et al. ReACT : long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma EGFR mutation variant III (EGFRvIII). SNO Congr. 2015;33:#2009.
   Google Scholar
• Roth P, Caroline H, Weller M. Corticosteroid use in neuro-oncology: an update. Neuro-Oncology Pract. 2015;2:6–12.
   PubMedGoogle Scholar
• Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139:1458–1471.
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Roth P. Immunological effects of chemotherapy and radiotherapy against brain tumors. Expert Rev Anticancer Ther. 2016;16:1–8.
   Web of Science ®Google Scholar
• Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci. 2012;109:17561–17566.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388:518–529.
   PubMed Web of Science ®Google Scholar
• Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72:1217–1222.
   PubMed Web of Science ®Google Scholar
• Junck L. Bevacizumab antiangiogenic therapy for glioblastoma. Neurology. 2011;76:414–415.
   PubMed Web of Science ®Google Scholar
• Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015;33:2735–2744.
   PubMed Web of Science ®Google Scholar
• Tabouret E, Boudouresque F, Barrie M, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. 2014;16:392–399.
   PubMed Web of Science ®Google Scholar
• Tabouret E, Boudouresque F, Farina P, et al. MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro Oncol. 2015;17:1174–1176.
   PubMed Web of Science ®Google Scholar
• Takano S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol. 2012;29:73–86.
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.
   PubMed Web of Science ®Google Scholar
• Tabouret E, Denicolai E, Delfino C, et al. Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma. J Neurooncol. 2016;130:1–7.
   PubMed Web of Science ®Google Scholar
• Peterson TE, Kirkpatrick ND, Huang Y, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A. 2016;113:4470–4475.
   PubMed Web of Science ®Google Scholar
• Li J-L, Sainson RCA, Oon CE, et al. DLL4-notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71:6073–6083.
   PubMed Web of Science ®Google Scholar
• Castro BA, Flanigan P, Jahangiri A, et al. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017. [Epub ahead of print].
   PubMedGoogle Scholar
• Piao Y, Liang J, Holmes L, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012;14:1379–1392.
   PubMed Web of Science ®Google Scholar
• Kessler T, Sahm F, Blaes J, et al. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget. 2015;6:31050–31068.
   PubMed Web of Science ®Google Scholar
• Boer JC, Walenkamp AME, Dunnen WFAD. Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies. Crit Rev Oncol Hematol. 2014;92:38–48.
   PubMed Web of Science ®Google Scholar
• Kuang R, Jahangiri A, Mascharak S, et al. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017;2:e88815.
   PubMed Web of Science ®Google Scholar
• Huang W-J, Chen -W-W, Zhang X. Glioblastoma multiforme: effect of hypoxia and hypoxia inducible factors on therapeutic approaches. Oncol Lett. 2016;12:2283–2288.
   PubMed Web of Science ®Google Scholar
• Piao Y, Liang J, Holmes L, et al. Acquired resistance to Anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19:4392–4403.
   PubMed Web of Science ®Google Scholar
• Iwadate Y. Epithelial mesenchymal transition in glioblastoma progression (Review). Oncol Lett. 2016;11:1615–1620.
   PubMed Web of Science ®Google Scholar
• Kloepper J, Riedemann L, Amoozgar Z, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016;113:4476–4481.
   PubMed Web of Science ®Google Scholar
• Piao Y, Park SY, Henry V, et al. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 2016;18:1230–1241.
   PubMed Web of Science ®Google Scholar
• De Palma M, Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim Biophys Acta - Rev Cancer. 2009;1796:5–10.
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–231.
   PubMed Web of Science ®Google Scholar
• Mao X-G, Wang C, Liu D-Y, et al. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma. Oncotarget. 2016;7:47808–47820.
   PubMed Web of Science ®Google Scholar
• Suchorska B, Weller M, Tabatabai G, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma - Results from the DIRECTOR trial. Neuro Oncol. 2016;18:549–556.
   PubMed Web of Science ®Google Scholar
• Ellingson BM, Harris RJ, Woodworth DC, et al. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials. Neuro Oncol. 2016;19:89–98.
   PubMed Web of Science ®Google Scholar